HK1211849A1 - 包含吉格列汀和二甲雙胍的組合藥物及其製備方法 - Google Patents

包含吉格列汀和二甲雙胍的組合藥物及其製備方法

Info

Publication number
HK1211849A1
HK1211849A1 HK15112746.5A HK15112746A HK1211849A1 HK 1211849 A1 HK1211849 A1 HK 1211849A1 HK 15112746 A HK15112746 A HK 15112746A HK 1211849 A1 HK1211849 A1 HK 1211849A1
Authority
HK
Hong Kong
Prior art keywords
gemigliptin
metformin
preparation
combination drug
drug
Prior art date
Application number
HK15112746.5A
Other languages
English (en)
Inventor
金根泰
尹德溢
朴基淑
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50477605&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1211849(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of HK1211849A1 publication Critical patent/HK1211849A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK15112746.5A 2012-10-08 2015-12-28 包含吉格列汀和二甲雙胍的組合藥物及其製備方法 HK1211849A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20120111404 2012-10-08
PCT/KR2013/008932 WO2014058188A1 (en) 2012-10-08 2013-10-07 Combination drug comprising gemigliptin and metformin, and method for the preparation thereof

Publications (1)

Publication Number Publication Date
HK1211849A1 true HK1211849A1 (zh) 2016-06-03

Family

ID=50477605

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15112746.5A HK1211849A1 (zh) 2012-10-08 2015-12-28 包含吉格列汀和二甲雙胍的組合藥物及其製備方法

Country Status (19)

Country Link
EP (1) EP2903602B1 (zh)
KR (1) KR101526553B1 (zh)
CN (2) CN104884051A (zh)
AU (1) AU2013330679B2 (zh)
BR (1) BR112015007360A8 (zh)
CL (1) CL2015000857A1 (zh)
DO (1) DOP2015000071A (zh)
HK (1) HK1211849A1 (zh)
MX (1) MX368184B (zh)
MY (1) MY174238A (zh)
PE (1) PE20150721A1 (zh)
PH (1) PH12015500653B1 (zh)
RU (1) RU2664422C2 (zh)
SG (1) SG11201502241XA (zh)
TW (1) TWI606848B (zh)
UA (1) UA114527C2 (zh)
UY (1) UY35065A (zh)
WO (1) WO2014058188A1 (zh)
ZA (1) ZA201501985B (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102496851B1 (ko) 2015-04-10 2023-02-08 제이더블유중외제약 주식회사 아나글립틴 또는 이의 약학적으로 허용 가능한 염 및 메트포르민 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물 및 그의 제조 방법
BR112019009709A2 (pt) * 2016-11-15 2019-08-13 Lg Chemical Ltd preparação de combinação.
WO2020091406A1 (ko) * 2018-10-31 2020-05-07 주식회사 엘지화학 제2형 당뇨병 치료용 약제학적 조성물
KR102633770B1 (ko) 2019-05-24 2024-02-02 주식회사 엘지화학 제2형 당뇨병 치료용 복합제제
CN112641776A (zh) * 2019-10-12 2021-04-13 江苏晶立信医药科技有限公司 一种以二甲双胍或其可药用盐和澳格列汀或其可药用盐为活性成分的药用组合物
PE20231638A1 (es) * 2020-08-14 2023-10-16 Lg Chemical Ltd Formulacion compuesta para tratamiento de diabetes mellitus tipo 2
CN112546013B (zh) * 2020-12-29 2022-06-10 平光制药股份有限公司 一种沙格列汀二甲双胍双层片及其制备工艺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20035A3 (cs) * 2000-07-06 2003-05-14 Metabasis Therapeutics, Inc. Kombinace FBPázových inhibitorů a antidiabetických činidel užitečná při léčení diabetes
WO2005060942A1 (en) * 2003-12-19 2005-07-07 Aurobindo Pharma Ltd Extended release pharmaceutical composition of metformin
AU2009220444A1 (en) * 2008-03-04 2009-09-11 Merck Sharp & Dohme Corp. Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-IV inhibitor
US8551524B2 (en) * 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
AR071175A1 (es) * 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
EP4209210A1 (en) * 2009-10-02 2023-07-12 Boehringer Ingelheim International GmbH Pharmaceutical compositions comprising bi-1356 and metformin
EP2356985A1 (en) * 2010-02-10 2011-08-17 LEK Pharmaceuticals d.d. Novel pharmaceutical compositions comprising a combination of metformin and sitagliptin
WO2012049566A1 (en) * 2010-10-14 2012-04-19 Japan Tobacco Inc. Combination therapy for use in treating diabetes
WO2012059416A1 (en) * 2010-11-02 2012-05-10 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of metabolic disorders
WO2012090225A2 (en) * 2010-12-29 2012-07-05 Nutracryst Therapeutics Private Limited Novel cocrystals / molecular salts of metformin with oleoylethanolamide as an effective anti-diabetic + anti- obesity agent
AR085689A1 (es) * 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2

Also Published As

Publication number Publication date
RU2664422C2 (ru) 2018-08-17
CN104884051A (zh) 2015-09-02
CL2015000857A1 (es) 2015-08-21
BR112015007360A8 (pt) 2018-08-14
EP2903602B1 (en) 2019-09-18
WO2014058188A1 (en) 2014-04-17
TWI606848B (zh) 2017-12-01
DOP2015000071A (es) 2018-06-30
MX368184B (es) 2019-09-23
UA114527C2 (uk) 2017-06-26
PH12015500653A1 (en) 2015-05-11
PH12015500653B1 (en) 2015-05-11
PE20150721A1 (es) 2015-05-23
AU2013330679B2 (en) 2016-10-06
EP2903602A4 (en) 2016-03-16
UY35065A (es) 2014-05-30
KR101526553B1 (ko) 2015-06-09
BR112015007360A2 (pt) 2017-07-04
ZA201501985B (en) 2016-01-27
TW201416095A (zh) 2014-05-01
AU2013330679A1 (en) 2015-04-09
MX2015004296A (es) 2015-08-07
CN110339176A (zh) 2019-10-18
SG11201502241XA (en) 2015-04-29
RU2015117523A (ru) 2016-11-27
MY174238A (en) 2020-04-01
KR20140045271A (ko) 2014-04-16
EP2903602A1 (en) 2015-08-12
AU2013330679A8 (en) 2015-04-16

Similar Documents

Publication Publication Date Title
IL233154A (en) Compounds, pharmaceuticals containing them and their uses
EP2881395A4 (en) PIPERAZINOTRIZOLE COMPOUND, PROCESS FOR PREPARING THE SAME AND USE THEREOF IN THE PREPARATION OF MEDICAMENT
HK1196819A1 (zh) 雜環化合物、含有所述化合物的藥物及其用途和其製備方法
HK1211849A1 (zh) 包含吉格列汀和二甲雙胍的組合藥物及其製備方法
EP2829267A4 (en) PHARMACEUTICAL TOPIRAMATE COMPOSITION WITH DELAYED RELEASE, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF
EP2742020A4 (en) N1-CYCLIC AMIN-N5-SUBSTITUTED BIGUANIDE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION THEREWITH
EP2937326A4 (en) PROCESS FOR THE PREPARATION OF 1, 3, 3, 3-TETRAFLUOROPROPENE
EP2813495A4 (en) 2-ARYLBENZOFURAN-7-FORMAMIDE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND USE THEREOF
EP2786982A4 (en) AMINO-PROPYLENE-GLYCOL DERIVATIVES, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF
EP2924042A4 (en) BIS-BETA-CARBOLINE COMPOUND AND METHOD OF MANUFACTURING, PHARMACEUTICAL COMPOSITION AND USE THEREOF
EP2837627A4 (en) AMIDOPYRIDINE DERIVATIVE AND USE THEREOF
HK1211570A1 (zh) 茚衍生物、其製備和作為藥物的用途
EP2752419A4 (en) SPIROBENZYLAMINE-PHOSPHINE, ITS PREPARATION METHOD AND USE
HK1212968A1 (zh) 氨基環丁烷衍生物、其製備方法及其用作藥物的用途
IL227544B (en) (r)- Leoplomide, a method for its preparation and its medical uses
EP2704570A4 (en) ACTIVE SUBSTANCES, PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
HK1209027A1 (zh) 囊泡製劑、用途和方法
PL2822388T3 (pl) Preparat owadobójczy, jego zastosowanie i sposób wytwarzania
IL239654B (en) Process for the preparation of 6alpha, 14alpha-ethanomorphinans from 7-beta mutants and 6alpha, 14alpha-ethanomorphinans from 7-beta mutants
EP2926811A4 (en) ARTEMISCULAR PHARMACEUTICAL COMPOSITION, MANUFACTURE AND USE
PL398496A1 (pl) Iminowa pochodna (-)-fenchonu i sposób jej wytwarzania
PL398018A1 (pl) Nowa diacylo-sn-glicero-3-fosfocholina oraz sposób jej otrzymywania
PL398021A1 (pl) Nowa diacylo-sn-glicero-3-fosfocholina oraz sposób jej otrzymywania
HK1198931A1 (zh) 獲得基於莫達非尼的藥物組合物的方法、獲得的藥物組合物及其應用
EP2781521A4 (en) NOVEL COMPOUND OF SPIROINDOLINE AND THERAPEUTIC AGENT CONTAINING THE SAME